<source id="z05db"></source>

      <label id="z05db"><th id="z05db"></th></label>
      1. ×

        R&D Progress

        Guided by the philosophy of "building a global brand through continuous innovation", we constantly optimize our product mix and enrich our research pipelines. We devote ourselves to the development of medicines for diabetes and other endocrine disorders diseases, in a bid to enhance our market competitiveness and lead the domestic industry.

        Milestones

        • 1985

          Fresh Ginseng oral liquid

        • 1989

          Zhennaoning Capsules

        • 1993

          Dongbao Gantai

        • 1998

          Recombinant Human Insulin Injection (Gansulin R)

        • 1999

          Isophane Protamine Recombinant Human Insulin Injection(Gansulin N)

        • 2002

          Mixed Protamine Human Insulin Injection(30R)(Gansulin 30R)

        • 2008

          Mixed Protamine Human Insulin Injection(50R)(Gansulin 50R)

        • 2014

          Mixed Protamine Human Insulin Injection(40R)

        • 2019

          Insulin Glargine Injection

        • 2021

          Insulin Aspart Injection

        • 2022

          Insulin Aspart 30 Injection

        • 2022

          Insulin Aspart 50 Injection

        • 1985

          Fresh Ginseng oral liquid

        • 1989

          Zhennaoning Capsules

        • 1993

          Dongbao Gantai

        • 1998

          Recombinant Human Insulin Injection (Gansulin R)

        • 1999

          Isophane Protamine Recombinant Human Insulin Injection(Gansulin N)

        • 2002

          Mixed Protamine Human Insulin Injection(30R)(Gansulin 30R)

        • 2008

          Mixed Protamine Human Insulin Injection(50R)(Gansulin 50R)

        • 2014

          Mixed Protamine Human Insulin Injection(40R)

        • 2019

          Insulin Glargine Injection

        • 2021

          Insulin Aspart Injection

        • 2022

          Insulin Aspart 30 Injection

        • 2022

          Insulin Aspart 50 Injection

        Product Pipeline

        Product Name Indications Preclinical IND Clinical NDA
        Mixed protamine zinc recombinant human insulin lispro injection 25R Diabetes requiring insulin therapy
        Mixed protamine zinc recombinant human insulin lispro injection 50R Diabetes requiring insulin therapy
        Insulin Degludec Injection Type 2 diabetes in adults
        Insulin Degludec and Liraglutide Injection Type 2 diabetes in adults
        Ultra-fast Insulin Lispro Injection(BC Lispro) Type 1 diabetes in adults
        Semaglutide Injection Type 2 diabetes in adults
        THDBH161 Acute gouty arthritis
        SGLT1/SGLT2/DPP4 Inhibitor Type 2 diabetes in adults
        THDBH110/111 Type 2 diabetes in adults
        THDBH120 Type 2 diabetes in adults
        THDBH120 Obesity
        URAT1 Inhibitor Gout/hyperuricemia
        THDBH150/151 Gout/hyperuricemia
        在线视频中文字幕久热,97久久精品人人槡人妻人…,日本黄网免费大全,中文字幕无码在线看片
        <source id="z05db"></source>

            <label id="z05db"><th id="z05db"></th></label>